The ‘Haves And Have-Nots’ Are Becoming Clearer In Cell And Gene Therapy

2023 saw a number of gene therapy companies go to the wall, but those that can combine clinical significance and commercial success can build sustainable businesses.

While 2023 saw several cell and gene therapy approvals that were genuine scientific and clinical breakthroughs, many smaller companies in the sector bore the brunt of the ongoing biopharma downturn.

Most notable among the sector’s milestones were the US Food and Drug Administration’s accelerated approval of Sarepta’s Duchenne muscular...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies